雷米普利对充血性心力衰竭患者Fas/Apo-1水平的影响

Effect of ramiprili on Fas/Apo-1 in patients with congestive heart failure

目的观察雷米普利对充血性心力衰竭(CHF)患者细胞凋亡抑制因子Fas/Apo-1的影响。方法酶联免疫方法检测84例CHF患者(雷米普利治疗42例;常规治疗42例)治疗前后及30例健康人血清中Fas/Apo-1水平。结果与健康人相比,84例CHF患者Fas/Apo-1水平显著生高(P<0.01);CHF患者Fas/Apo-1水平随着心功能损害加重而升高,各组间差异有显著性(P<0.05);雷米普利组与常规治疗组治疗前Fas/Apo-1水平两组间差异无显著性(P>0.05);与常规治疗组相比,雷米普利组治疗后血清中Fas/Apo-1水平降低更为明显(P<0.01)。结论CHF患者血清中Fas/Apo-1水平可反映心力衰竭的程度,雷米普利改善CHF患者心脏功能的作用可能与其抑制心肌细胞凋亡的机制有关。

[Objective] To observe the effect of ramipril on the cardiac function and serum level of Fas/Apo-1 in patients with congestive heart failure （CHF）. [Methods] Level of serum Fas/Apo-1 was determined by enzymelinked immunosorbeat assy （ELLSA） in 84 CHF cases （42 treated with ramiprili and 42 with conventional method） and 30 heartly cases as control. [Results] The level of serum Fas/Apo-1 in the 84 CHF cases was much higher than that in the control cases （P 〈0.01 ）and increased significantly with the aggration of cardiac dysfunction. Before treatment, there was no significant difference in serum level of Fas/Apo-1 between ramiprili group and conventional group, but after treatment, the Fas/Apo-1 level in the ramiprili group was significantly lower （P 〈0.01）than that in conventional group. [Conclusion] Level of circulating Fas/Apo-1 can be used to determine the cardiac dyfunction degree and ramipril may play an important role in protecting cardic function by inhibiting the myocardium apoptosis process in patients with CHF.